Gene Editing and Gene-Based Therapeutics for Cardiomyopathies

Joyce C. Ohiri, Elizabeth M. McNally*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


With an increasing understanding of genetic defects leading to cardiomyopathy, focus is shifting to correcting these underlying genetic defects. One approach involves treating mutant RNA through antisense oligonucleotides; the first drug has received regulatory approval to treat specific mutations associated with Duchenne muscular dystrophy. Gene editing is being evaluated in the preclinical setting. For inherited cardiomyopathies, genetic correction strategies require tight specificity for the mutant allele. Gene-editing methods are being tested to create deletions that may be useful to restore protein expression by through the bypass of mutations that restore protein production. Site-specific gene editing, which is required to correct many point mutations, is a less efficient process than inducing deletions.

Original languageEnglish (US)
Pages (from-to)179-188
Number of pages10
JournalHeart Failure Clinics
Issue number2
StatePublished - Apr 2018


  • Antisense oligonucleotides
  • Cardiomyopathy
  • Gene editing
  • Genetic correction
  • Genetic mutations
  • Heart failure
  • Muscular dystrophy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Gene Editing and Gene-Based Therapeutics for Cardiomyopathies'. Together they form a unique fingerprint.

Cite this